Related Experiment Video
Updated: Jul 2, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype
Elena Y Dobrikova1, Trevor Broadt, Judith Poiley-Nelson
1Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA.
Abstract:
Many viruses, either naturally occurring or as a result of genetic manipulation, exhibit conditional replication in transformed cells. This principle is the basis for experimental therapeutic approaches exploiting the oncolytic potential of such agents without the danger of collateral damage to resistant normal tissues. One of the potential obstacles to these approaches is the possibility of genetic adaptation of oncolytic viruses upon replication in susceptible tumor tissues. Genetic variation can reverse genetic manipulations of parental viral genomes that determine attenuation of virulence, selective tumor cell tropism or other desirable traits. Alternatively, it may convey new properties not originally associated with parental strains, e.g., adaptation to a human host range. We examined genetic stability of an oncolytic nonpathogenic poliovirus recombinant considered for therapy of recurrent glioblastoma multiforme (GBM). This was done by serial passage experiments in glioma xenografts in vivo and investigation of phenotypic and genotypic markers of attenuation. Intratumoral inoculation of oncolytic poliovirus produced efficient tumor regress and elimination without altering temperature-sensitive growth, selective cytotoxicity, or genetic markers of attenuation of virus recovered from inoculated animals. Our studies demonstrate that active viral oncolysis of malignant glioma does not alter the conditional replication properties of oncolytic nonpathogenic poliovirus recombinants.
Insights
Oncolytic poliovirus effectively eliminated glioblastoma in vivo without genetic changes. This demonstrates the virus
Area of Science:
- Virology
- Oncology
- Gene Therapy
Background:
- Viruses can be engineered for conditional replication in cancer cells, forming the basis of oncolytic virotherapy.
- Potential genetic adaptation of oncolytic viruses during tumor replication poses a risk to therapeutic efficacy and safety.
- Maintaining viral genetic stability is crucial for predictable oncolytic activity and safety.
Purpose of the Study:
- To assess the genetic stability of an oncolytic poliovirus recombinant used for glioblastoma multiforme (GBM) therapy.
- To investigate whether viral replication within tumors alters key markers of attenuation and tumor cell targeting.
- To confirm the safety and efficacy of oncolytic poliovirus in a preclinical glioblastoma model.
Main Methods:
- Serial passage of an oncolytic poliovirus recombinant in glioma xenografts in vivo.
- Evaluation of phenotypic markers, including temperature-sensitive growth and selective cytotoxicity.
- Analysis of genotypic markers to detect any genetic alterations in the recovered virus.
Main Results:
- Intratumoral inoculation led to significant tumor regression and elimination.
- The recovered oncolytic poliovirus retained its temperature-sensitive growth properties.
- Selective cytotoxicity against glioma cells and original genetic markers of attenuation remained unchanged.
- No evidence of genetic adaptation or reversal of engineered traits was observed.
Conclusions:
- Oncolytic poliovirus demonstrates robust genetic stability during active replication in malignant glioma.
- Viral oncolysis of GBM does not compromise the conditional replication characteristics of the engineered poliovirus.
- These findings support the therapeutic potential of genetically stable oncolytic poliovirus recombinants for GBM treatment.
